A University of Maryland School of Medicine researcher will lead the coordinating center for a consortium of our nation's most prominent scientists in the field of stem cell research. Michael L. Terrin, M.D.,C.M.,M.P.H., professor of Epidemiology and Preventive Medicine, was chosen by the National Heart, Lung and Blood Institute (NHLBI) to coordinate the research of this consortium of national experts, which will be called the NHLBI Progenitor Cell Biology Consortium. The coordinating center will be funded by a $30 million grant over seven years.
"This consortium was developed to bring together the best and brightest researchers from around the country, in the new and rapidly advancing field of stem and progenitor cell biology. They come from several specialties -- cardiology, hematology and pulmonary medicine. All are doing cutting edge research in this exciting new field," says Dr. Terrin.
E. Albert Reece, M.D., Ph.D., M.B.A, vice president for medical affairs at the University of Maryland and dean of the School of Medicine states, "We have the full resources of the University of Maryland School of Medicine available for the benefit of this project, including a world-class Center for Stem Cell Biology and Regenerative Medicine."
Stem cells are uncommitted cells that can change into many types of mature functional cell and can divide indefinitely. Progenitor cells, on the other hand, are partially committed as far as the kinds of cell they can become and how many times they can divide. Once stem cells start to commit to a cell type, they create progenitor cells. One major goal of this research consortium is to use these stem and progenitor cells as regenerative therapy to replace damaged tissues and organs.
The researchers will share their strategies and techniques to identify and characterize how these cells differentiate. Together they will address the challenges of discovering new potential thera
|Contact: Karen Buckelew|
University of Maryland Medical Center